Live price temporarily unavailable.
Hyperfine (HYPR) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $294.0K | $1.50M | $6.81M | $11.0M | $12.9M | $13.6M |
| Growth (year over year) | — | +408.8% | +355.5% | +61.9% | +16.8% | +5.2% |
| Gross profit | −$477.0K | −$1.17M | $907.0K | $4.76M | $5.89M | $6.75M |
| Gross margin | −162.2% | −78.0% | 13.3% | 43.1% | 45.7% | 49.8% |
| Operating income | −$23.5M | −$64.9M | −$73.9M | −$48.1M | −$43.2M | −$37.1M |
| Operating margin | −7990.1% | −4336.1% | −1084.2% | −436.1% | −335.3% | −273.4% |
| Net income | −$23.4M | −$64.9M | −$44.2M | −$44.2M | −$40.7M | −$35.6M |
| Net margin | −7968.4% | −4335.0% | −649.2% | −401.0% | −315.9% | −262.3% |
| EPS (diluted) | −$15.38 | −$17.57 | −$1.04 | −$0.62 | −$0.56 | −$0.43 |
| Balance sheet | ||||||
| Cash and equivalents | $62.7M | $188.5M | $117.5M | $75.2M | $37.6M | $35.1M |
| Total assets | $71.5M | $202.5M | $134.1M | $94.2M | $58.9M | $55.3M |
| Total liabilities | $4.29M | $16.2M | $10.3M | $9.80M | $9.86M | $14.3M |
| Long-term debt | — | — | — | — | — | $0 |
| Shareholders' equity | −$61.1M | $186.2M | $123.7M | $84.4M | $49.0M | $41.0M |
| Cash flow | ||||||
| Operating cash flow | −$21.5M | −$47.2M | −$72.3M | −$41.8M | −$38.8M | −$27.9M |
| Capital expenditure | $1.57M | $2.71M | $585.0K | $804.0K | $383.0K | $1.19M |
| Free cash flow | −$23.1M | −$49.9M | −$72.9M | −$42.6M | −$39.1M | −$29.1M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.64M | $2.32M | $2.14M | $2.70M | $3.44M | $5.29M | $3.90M | $3.90M |
| Growth (year over year) | +56.4% | −13.6% | −35.1% | −25.8% | −5.7% | +128.0% | +82.6% | +44.8% |
| Gross profit | $1.91M | $826.0K | $883.0K | $1.33M | $1.85M | $2.69M | $1.98M | $1.98M |
| Gross margin | 52.4% | 35.6% | 41.3% | 49.3% | 53.8% | 50.9% | 50.7% | 50.7% |
| Operating income | −$11.0M | −$10.8M | −$10.9M | −$9.60M | −$8.92M | −$7.67M | −$8.56M | −$8.47M |
| Operating margin | −300.9% | −463.8% | −510.2% | −355.9% | −259.5% | −144.9% | −219.3% | −216.9% |
| Net income | −$10.3M | −$10.4M | −$9.42M | −$9.22M | −$11.0M | −$5.91M | −$8.62M | −$9.30M |
| Net margin | −283.4% | −447.7% | −440.7% | −342.2% | −320.6% | −111.7% | −220.9% | −238.2% |
| EPS (diluted) | −$0.14 | −$0.14 | −$0.12 | −$0.12 | −$0.14 | −$0.05 | −$0.09 | −$0.09 |
| Balance sheet | ||||||||
| Cash and equivalents | $45.8M | $37.6M | $33.1M | $25.4M | $21.6M | $35.1M | $40.8M | $43.5M |
| Total assets | $69.4M | $58.9M | $53.4M | $45.2M | $41.5M | $55.3M | $60.3M | $63.0M |
| Total liabilities | $11.1M | $9.86M | $10.3M | $10.1M | $14.6M | $14.3M | $26.0M | $26.2M |
| Long-term debt | — | — | — | — | — | $0 | $13.1M | $13.2M |
| Shareholders' equity | $58.3M | $49.0M | $43.1M | $35.1M | $26.9M | $41.0M | $34.4M | $36.8M |
| Cash flow | ||||||||
| Operating cash flow | −$8.52M | −$8.36M | −$9.25M | −$7.91M | −$5.58M | −$5.21M | −$9.01M | −$7.27M |
| Capital expenditure | $159.0K | $8.00K | $472.0K | $520.0K | $130.0K | $63.0K | $242.0K | $30.0K |
| Free cash flow | −$8.68M | −$8.37M | −$9.72M | −$8.43M | −$5.71M | −$5.27M | −$9.25M | −$7.30M |
From Hyperfine's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Hyperfine in our feed yet.